# Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib

> **NCT02185560** · — · ACTIVE_NOT_RECRUITING · sponsor: **Bayer** · enrollment: 453 (actual)

## Conditions studied

- Thyroid Carcinoma

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)

## Key facts

- **NCT ID:** NCT02185560
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-06-27
- **Primary completion:** 2020-02-27
- **Final completion:** 2026-09-30
- **Target enrollment:** 453 (ACTUAL)
- **Last updated:** 2026-04-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02185560

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02185560, "Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT02185560. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*